Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, Temozolomide, and Radiation in Newly Diagnosed Glioblastoma
NCT03174197Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 21 months and Dose-limiting Toxicities at 10 weeks. Started Jun 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03174197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174197.